Other exchanges or trading platforms where Scancell Holdings plc securities are admitted or traded:
Scancell Holdings securities are listed on AIM, and the latest share price is shown here
The number of securities in issue:
The company has an issued share capital of 815,218,831 ordinary shares of 0.1p each, all of which are called up and fully paid.
Pursuant to the License and Supply Agreement (‘the Agreement’) dated 13 July 2009, the Company has granted options over 3,184,630 ordinary shares to ICHOR at 4.5p per share.
Directors’ Share Options:
The Company has granted the following options to Directors of the Company.
| Option holder |
Option price per ordinary share |
Number of ordinary shares under option |
Last day of exercise period |
| Sally Adams |
10.5p |
2,500,000 |
30 January 2028 |
| Sally Adams |
8.15p |
1,000,000 |
30 April 2030 |
| John Chiplin |
17.0p |
3,000,000 |
18 April 2026 |
| John Chiplin |
8.15p |
1,000,000 |
30 April 2030 |
| Lindy Durrant |
10.5p |
9,000,000 |
30 January 2028 |
| Lindy Durrant |
8.15p |
1,000,000 |
30 April 2030 |
| Lindy Durrant |
4.5p |
3,850,000 |
30 July 2023 |
|
Richard Goodfellow
|
33.2p |
3,500,000 |
31 December 2023 |
| Richard Goodfellow |
8.15p |
1,000,000 |
30 April 2030 |
| Richard Goodfellow |
4.5p |
2,880,000 |
30 July 2023 |
| Clifford Holloway |
10.5p |
3,000,000 |
30 January 2028 |
| Clifford Holloway |
8.15p |
1,000,000 |
30 April 2030 |
In addition to the above, the Company has granted options over 2,396,016 shares of the Company to various other persons at exercise prices between 5p and 33.2p.
Percentage of AIM securities not in public hands:
As at 17 February 2021 the percentage of AIM securities not in public hands was: 52.04%
Restrictions on the transfer of securities:
There are no restrictions on the transfer of shares.
Identity and percentage holdings of significant shareholders:
As at 17 February 2021 the identity and percentage holdings of significant shareholders were:
| |
Ordinary shares at 0.1p each |
| |
Number |
Percentage |
| Redmile Group LLC |
237,306,384 |
29.11% |
| Vulpes Life Science Fund |
117,829,029 |
14.45% |
| Calculus Capital |
49,844,165 |
6.11% |
| Scancell Holdings plc directors and related holdings |
19,301,501 |
2.37% |